Beneficial Effects of Statins in Coronary Artery Disease

Abstract

Spanish

French

OBJECTIVE:

To review the benefits of statins in coronary artery disease management beyond their cholesterol-lowering effects.

DATA SOURCES:

A MEDLINE search (1966–May 2000) was conducted using the following terms: lovastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, endothelium, plaque stabilization, antithrombotic effects.

STUDY SELECTION:

English-language human studies and case reports.

DATA EXTRACTION:

Studies published demonstrating other mechanisms of statins' clinical beneficial effects were evaluated and reviewed.

DATA SYNTHESIS:

The understanding of the pharmacologic effects of statins has led to the realization that the benefits of these agents extend beyond simply lowering cholesterol. These properties include beneficial effects on vessel endothelial tissue; decreased low-density lipoprotein oxidation and inflammation; ability to stabilize atherosclerotic plaques and perhaps promote regression; proliferative effects on smooth-muscle growths, possibly strengthening atherosclerotic plaques; antithrombotic effects by inhibiting platelet aggregation and stimulation of fibrinolytic factors; and improvement of blood viscosity and flow. With these actions, statins may benefit the situation of long-term atherosclerotic plaque formation and the setting of acute coronary syndrome.

CONCLUSIONS:

Further large-scale studies are needed to determine the clinical importance and validity of these postulated beneficial effects of statins.

Keywords

statins endothelial function plaque stabilization antithrombotic effects

Get full access to this article

View all access options for this article.

References

Brown

Albers

Frisher

Schaefer

Lin

Kaplan

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289–98.

Blankenhorn

Azen

Kramsch

Mack

Cashin-Hemphill

Hodis

Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969–76.

Waters

Higginson

Gladstone

Kimball

Le May

Boccuzzi

Effects of monotherapy with HMG Co-A reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959–68.

MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633–8.

Jukema

Bruschke

AVG

van Boven

Reiber

Bal

Zwinderman

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91: 2528–40.

Pitt

Mancini

GBJ

Ellis

Rosman

Park

McGovern

. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1994;26:1133–9.

Sacks

Pfeiffer

Moye

Rouleau

Rutherford

Cole

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9.

Shepherd

Cobbe

Ford

Isles

Lorimen

MacFarlane

Prevention of coronary heart disease with pravastatin in patients with hypercholesterolemia. N Engl J Med 1995;333:1301–7.

Downs

Clearfield

Weis

Whitney

Shapiro

Beere

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol events. JAMA 1998;279:1615–22.

10.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

11.

The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.

12.

Gibbons

Dzau

. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431–8.

13.

Basha

Sowers

. Atherosclerosis: An update. Am Heart J 1995;131: 1192–202.

14.

Zeiher

Drexler

Saurbier

Just

. Endothelium mediated coronary blood flow modulation in humans: Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652–62.

15.

Chobanian

. Pathophysiology of atherosclerosis. Am J Cardiol 1992;70:3G–7G.

16.

Diaz

Frei

Vita

Keaney

. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408–16.

17.

Berliner

Navab

Fogelman

Frank

Demer

Edwards

Atherosclerosis: Basic mechanisms oxidation, inflammation, and genetics. Circulation 1995;91:2488–96.

18.

White

. Unmet therapeutic needs in the management of acute ischemics. Am J Cardiol 1997;80(4A):2B–10B.

19.

Dobesh

Latham

. Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors. Pharmacotherapy 1998;18:663–85.

20.

Fuster

Jang

. Role of platelet-inhibitor agents in coronary artery disease. In: Topol

, ed. Textbook of interventional cardiology. 2nd ed. Vol. 1. Philadelphia: WB Saunders, 1994:3–22.

21.

Haines

Bussey

. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995;29:892–905.

22.

Fuster

Badimore

Cheseboro

. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992;326:242–50.

23.

Furie

. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800–6.

24.

Bates

Weitz

. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and huridin. Am J Cardiol 1998;82(24B):12P–8P.

25.

Folland

Vogel

Hartigan

Bates

Beauman

Fortin

Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single vessel coronary artery disease. Circulation 1994;89:2005–14.

26.

Ambrose

Tannenbaum

Alexopoulos

Hjemdahl-Monsen

Leavy

Weiss

Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56–62.

27.

Van Boven

Jukema

Zwinderman

Crijns

Lie

Bruschke

. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996;94:1503–5.

28.

Andrews

Raby

Barry

Naimi

Allred

Ganz

Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324–8.

29.

Eichstadt

Eskotter

Hoffmann

Amthauer

Weidinger

. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995;76:122A–5A.

30.

De Divitiis

Rubba

Di Somma

Liguori

Galderisi

Montefusco

Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol 1996;78:763–8.

31.

Mostaza

Gomez

Gallardo

Salazar

Martin-Jadraque

Plaza-Celemin

Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol level. J Am Coll Cardiol 2000;35:76–82.

32.

Ross

Allen

Connelly

Korenblat

Smith

Bishop

Clinical outcomes in statin treatment trials. Arch Intern Med 1999;159:1793–802.

33.

Atkins

Psaty

Koepsell

Lonstreth

Larson

. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized controlled trials. Ann Intern Med 1993;119:136–45.

34.

Leung

Lau

Wong

. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496–500.

35.

Vogel

. Cholesterol lowering and endothelial function. Am J Med 1999;107:479–87.

36.

Egashira

Hirooka

Kai

Sugimachi

Suzuki

Inou

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519–24.

37.

Anderson

Meredith

Yeung

Frei

Selwyn

Ganz

. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488–93.

38.

Treasure

Klein

Weintraub

Talley

Stillabower

Kosinski

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481–7.

39.

O'Driscoll

Green

Taylor

. Simvastatin, an HMG—coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126–31.

40.

John

Schlaich

Langenfeld

Weihprecht

Schmitz

Weidinger

Increased bioavailability of nitric oxide after lipid lowering therapy in hypercholesterolemic patients. Circulation 1998;98:211–6.

41.

Dupuis

Tardif

Theroux

. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 1999;99:3227–33.

42.

Vogel

Corretti

Plotnick

. The mechanism of improvement in endothelial function by pravastatin: direct effect or through cholesterol lowering. Presented at American College of Cardiology meeting. Atlanta, GA, March 28–April 1, 1998.

43.

Stranzniky

Howes

Lam

Louis

. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995;75:582–6.

44.

Falk

Shah

Fuster

. Coronary plaque disruption. Circulation 1995;92:657–71.

45.

Vaughan

Murphy

Buckley

. Statins do more than just lowering cholesterol. Lancet 1996;348:1079–82.

46.

Keidar

Aviram

Maor

Oiknine

Brook

. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies. Br J Clin Pharmacol 1994;13:513–9.

47.

Dangas

Badimon

Smith

Unger

Levine

Shao

Pravastatin therapy in hyperlipidemia effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294–304.

48.

Brown

Zhao

. Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am J Cardiol 1998;82(10B):49T–52T.

49.

Salonen

Nyyssonen

Porkkala-Sarataho

Salmen

. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995;76:34C–9C.

50.

Giroux

Davignon

Naruszewicz

. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte– Derived macrophages. Biochim Biophys Acta 1993;1165:335–8.

51.

Hoffman

Brook

Aviram

. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies. Atherosclerosis 1992;93:105–13.

52.

Aviram

Dankner

Cogan

Hochgraf

Brook

. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism 1992;41:229–35.

53.

Brosche

Kral

Summa

Platt

. Effective lovastatin therapy in elderly hypercholesterolemic patients — An antioxidative impact? Arch Gerontol Geriatr 1996;22:207–21.

54.

Weber

Erl

Weber

. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212–7.

55.

Kempen

HJM

Vermeer

de Wit

Havekes

. Vastatins inhibit cholesterol ester accumulation in human monocyte– Derived macrophages. Arterioscler Thromb 1991;11:146–53.

56.

Katznelson

Kobashigawa

. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int 1995;48:S-112–S-115.

57.

Negre-Aminou

van Vliet

van Erck

van Thiel

van Leeuwen

Cohen

. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997;1345:259–68.

58.

Corsini

Pazzucconi

Arnaboldi

Pfister

Fumagalli

Paoletti

Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998;31:773–8.

59.

Igarashi

Takeda

Mori

Ishibashi

Kamatsu

Takahashi

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997;120:1172–8.

60.

Altman

. Assessment of effects of lipid-lowering drugs on hemostasis. Am J Cardiol 1998;81(8A):73F–4F.

61.

Notarbartolo

Davi

Averna

Barbagallo

Ganci

Giammarresi

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247–51.

62.

Mayer

Eller

Brauer

Solleder

Schafer

Keller

Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992;64:196–201.

63.

Lacoste

Lam

JYT

. Comparative effect of pravastatin and simvastatin on platelet—thrombus formation in hypercholesterolemic coronary patients (abstract). J Am Coll Cardiol 1996;27:413A.

64.

Rosenson

Tangney

. Antiatherothrombotic properties of statins. JAMA 1998;279:1643–50.

65.

Sandset

Lund

Norseth

Abildgaard

Ose

Treatment with hydroxymethylglutaryl coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991;11:138–45.

66.

Wierzbicki

Lumb

Semra

Crook

. Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:560–1.

67.

Marais

Firth

Bateman

Byrnes

Martens

Mountney

. Atorvastatin: An effective agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:1527–32.

68.

Davidson

McKenney

Stein

Schrott

Bakker-Arkema

Fayyad

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79:1475–81.

69.

Velussi

Cemigi

Tortal

Merni

. Atorvastatin for the management of type 2 diabetic patients with dyslipidemia. A mid-term (9 months) treatment experience. Diabetes Nutr Metab 1999;12:407–12.

70.

Tsuda

Satoh

Kitadai

Takahashi

Izumi

Hasomi

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996;122:225–33.

71.

Branchi

Rovellini

Sommariva

Gugliandolo

Fasoli

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241–3.

72.

Ridker

Rifal

Pfeffer

Sacks

Braunwald

. Long-term effects of pravastatin on plasma concentration of C reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230–5.

73.

Isaacsohn

Setaro

Nicholas

Davey

Diotalevi

Christian-Son

Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994;73;5–7.

74.

Bevilacqua

Bettica

Milani

Vago

Rogolino

Righini

Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997;79:84–7.

75.

Mitropoulos

Armitage

Collins

Meade

Reeves

Wallendszusk

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J 1997;18:235–41.

76.

Hunninghake

Stein

Mellies

. Effects of one year of treatment with pravastatin, an HMG-CoA. J Clin Pharmacol 1993;33:574–80.

77.

Slunga

Johnson

Dahlen

. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 1992;43:369–73.

78.

Koenig

Hehr

Ditshuneit

Kuhn

Ernst

Rosenthal

Lovastatin alters blood rheology in primary hyperlipoproteinemia: Dependence on lipoprotein (a)?

J Clin Pharmacol 1992;32:539–45.

79.

Koppensteiner

Minar

Ehringer

. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 1990;83:53–8.

80.

Sposito

Mansur

Coelho

Nicolau

Ramires

JAF

. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497–9.

81.

Pitt

Waters

Brown

van Boven

Schwartz

Title

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70–6.

Beneficial Effects of Statins in Coronary Artery Disease — Beyond Lowering Cholesterol

Abstract

OBJECTIVE:

DATA SOURCES:

STUDY SELECTION:

DATA EXTRACTION:

DATA SYNTHESIS:

CONCLUSIONS:

Keywords

Get full access to this article

References